Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Valve Prosthesis Implantation | 5 | 2022 | 23 | 2.470 |
Why?
|
| Extracorporeal Membrane Oxygenation | 5 | 2022 | 21 | 2.290 |
Why?
|
| Blood Vessel Prosthesis Implantation | 4 | 2022 | 20 | 1.830 |
Why?
|
| Heart Neoplasms | 4 | 2021 | 11 | 1.810 |
Why?
|
| Endocarditis | 3 | 2022 | 10 | 1.700 |
Why?
|
| Postoperative Complications | 7 | 2022 | 804 | 1.160 |
Why?
|
| Endocarditis, Bacterial | 3 | 2022 | 11 | 1.030 |
Why?
|
| Humans | 39 | 2023 | 22592 | 0.930 |
Why?
|
| Cardiac Surgical Procedures | 7 | 2019 | 35 | 0.820 |
Why?
|
| Marfan Syndrome | 1 | 2023 | 4 | 0.810 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2022 | 9 | 0.780 |
Why?
|
| Female | 25 | 2023 | 12734 | 0.780 |
Why?
|
| Aneurysm, False | 2 | 2016 | 6 | 0.780 |
Why?
|
| Heart Ventricles | 4 | 2017 | 76 | 0.770 |
Why?
|
| Male | 24 | 2022 | 12260 | 0.760 |
Why?
|
| Treatment Outcome | 11 | 2022 | 2915 | 0.760 |
Why?
|
| Pulmonary Valve | 1 | 2022 | 8 | 0.760 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2012 | 7 | 0.720 |
Why?
|
| Aortic Aneurysm, Thoracic | 3 | 2016 | 10 | 0.720 |
Why?
|
| Stents | 2 | 2016 | 74 | 0.720 |
Why?
|
| Pleural Neoplasms | 1 | 2021 | 11 | 0.720 |
Why?
|
| Thymus Neoplasms | 1 | 2021 | 12 | 0.710 |
Why?
|
| Mesothelioma | 1 | 2021 | 14 | 0.710 |
Why?
|
| Reoperation | 4 | 2022 | 742 | 0.690 |
Why?
|
| Hospital Mortality | 4 | 2020 | 126 | 0.690 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2020 | 9 | 0.680 |
Why?
|
| Heart Aneurysm | 2 | 2013 | 5 | 0.670 |
Why?
|
| Lung Diseases | 1 | 2020 | 36 | 0.670 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 33 | 0.660 |
Why?
|
| Aortic Valve | 5 | 2020 | 22 | 0.640 |
Why?
|
| Heart Atria | 2 | 2016 | 20 | 0.630 |
Why?
|
| Vascular Surgical Procedures | 3 | 2021 | 22 | 0.620 |
Why?
|
| Coronary Artery Bypass | 4 | 2015 | 22 | 0.610 |
Why?
|
| Aortic Aneurysm | 2 | 2016 | 10 | 0.600 |
Why?
|
| Retrospective Studies | 11 | 2022 | 2954 | 0.600 |
Why?
|
| Shock, Cardiogenic | 1 | 2019 | 8 | 0.600 |
Why?
|
| Stroke | 1 | 2022 | 236 | 0.600 |
Why?
|
| Middle Aged | 19 | 2021 | 7800 | 0.590 |
Why?
|
| Aged | 17 | 2021 | 7300 | 0.570 |
Why?
|
| United States | 7 | 2023 | 1741 | 0.570 |
Why?
|
| Adult | 12 | 2023 | 6826 | 0.570 |
Why?
|
| Radiography, Thoracic | 2 | 2015 | 23 | 0.570 |
Why?
|
| Sternotomy | 2 | 2015 | 2 | 0.560 |
Why?
|
| Sarcoma | 1 | 2020 | 140 | 0.540 |
Why?
|
| Bioprosthesis | 2 | 2017 | 6 | 0.540 |
Why?
|
| Endarterectomy | 1 | 2016 | 1 | 0.520 |
Why?
|
| Femoral Artery | 1 | 2016 | 5 | 0.520 |
Why?
|
| Intermittent Claudication | 1 | 2016 | 3 | 0.520 |
Why?
|
| Peripheral Arterial Disease | 1 | 2016 | 5 | 0.520 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 48 | 0.510 |
Why?
|
| Thoracotomy | 3 | 2015 | 29 | 0.510 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 529 | 0.500 |
Why?
|
| Cause of Death | 1 | 2016 | 49 | 0.500 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2016 | 13 | 0.500 |
Why?
|
| Endovascular Procedures | 1 | 2016 | 28 | 0.490 |
Why?
|
| Pneumopericardium | 1 | 2015 | 1 | 0.470 |
Why?
|
| Intestinal Mucosa | 1 | 2016 | 155 | 0.460 |
Why?
|
| Heart Failure | 2 | 2017 | 138 | 0.450 |
Why?
|
| Cardiopulmonary Bypass | 5 | 2016 | 17 | 0.450 |
Why?
|
| Mandibulofacial Dysostosis | 1 | 2013 | 1 | 0.410 |
Why?
|
| Sinus of Valsalva | 1 | 2013 | 3 | 0.410 |
Why?
|
| Aortic Valve Stenosis | 1 | 2013 | 18 | 0.400 |
Why?
|
| Calcinosis | 1 | 2013 | 43 | 0.400 |
Why?
|
| Coronary Artery Disease | 2 | 2012 | 123 | 0.390 |
Why?
|
| Heart-Assist Devices | 1 | 2012 | 18 | 0.370 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2016 | 574 | 0.370 |
Why?
|
| Thoracic Arteries | 1 | 2011 | 2 | 0.360 |
Why?
|
| Hematoma | 1 | 2011 | 17 | 0.360 |
Why?
|
| Fibroma | 1 | 2011 | 5 | 0.350 |
Why?
|
| Cocaine-Related Disorders | 1 | 2011 | 13 | 0.350 |
Why?
|
| Hospitalization | 2 | 2023 | 281 | 0.330 |
Why?
|
| Prosthesis Failure | 1 | 2013 | 412 | 0.330 |
Why?
|
| Risk Assessment | 3 | 2019 | 537 | 0.320 |
Why?
|
| Hemorrhage | 2 | 2020 | 72 | 0.310 |
Why?
|
| Heart Arrest, Induced | 3 | 2013 | 3 | 0.310 |
Why?
|
| Myocardial Infarction | 2 | 2007 | 124 | 0.300 |
Why?
|
| Pericarditis | 1 | 2007 | 1 | 0.260 |
Why?
|
| Risk Factors | 4 | 2022 | 1955 | 0.250 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 3657 | 0.240 |
Why?
|
| Arterioles | 3 | 2012 | 11 | 0.210 |
Why?
|
| Biopsy | 2 | 2016 | 188 | 0.210 |
Why?
|
| Postpartum Period | 1 | 2023 | 20 | 0.200 |
Why?
|
| Lower Extremity | 1 | 2022 | 33 | 0.190 |
Why?
|
| Catheterization | 1 | 2022 | 40 | 0.190 |
Why?
|
| Length of Stay | 2 | 2022 | 293 | 0.190 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2016 | 3 | 0.190 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2013 | 30 | 0.190 |
Why?
|
| Diabetes Mellitus | 2 | 2013 | 101 | 0.190 |
Why?
|
| Propensity Score | 1 | 2021 | 33 | 0.180 |
Why?
|
| Renal Dialysis | 1 | 2022 | 71 | 0.180 |
Why?
|
| Ischemia | 1 | 2021 | 22 | 0.180 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 1403 | 0.180 |
Why?
|
| Incidence | 1 | 2023 | 618 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2013 | 147 | 0.170 |
Why?
|
| Acute Disease | 1 | 2021 | 161 | 0.170 |
Why?
|
| SEER Program | 1 | 2020 | 32 | 0.170 |
Why?
|
| Aorta | 2 | 2021 | 16 | 0.170 |
Why?
|
| Young Adult | 3 | 2020 | 1607 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 7 | 0.170 |
Why?
|
| Time Factors | 4 | 2016 | 1247 | 0.170 |
Why?
|
| Myocardial Ischemia | 1 | 2021 | 44 | 0.160 |
Why?
|
| Adipose Tissue | 1 | 2021 | 72 | 0.160 |
Why?
|
| Myocardium | 2 | 2013 | 100 | 0.160 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 302 | 0.160 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 269 | 0.160 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 344 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 40 | 0.150 |
Why?
|
| Heparin | 1 | 2019 | 23 | 0.150 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 120 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 95 | 0.140 |
Why?
|
| Infant | 1 | 2020 | 478 | 0.140 |
Why?
|
| Anticoagulants | 1 | 2019 | 83 | 0.140 |
Why?
|
| Prognosis | 1 | 2020 | 719 | 0.140 |
Why?
|
| Child, Preschool | 1 | 2020 | 561 | 0.140 |
Why?
|
| Adolescent | 2 | 2020 | 1855 | 0.140 |
Why?
|
| Infant, Newborn | 1 | 2020 | 526 | 0.140 |
Why?
|
| Heart Transplantation | 1 | 2017 | 28 | 0.130 |
Why?
|
| Graft Rejection | 1 | 2017 | 61 | 0.130 |
Why?
|
| Polyethylene Terephthalates | 1 | 2017 | 3 | 0.130 |
Why?
|
| Heart Valve Prosthesis | 1 | 2017 | 11 | 0.130 |
Why?
|
| Mitral Valve Stenosis | 1 | 2016 | 1 | 0.130 |
Why?
|
| Heterografts | 1 | 2016 | 16 | 0.130 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2016 | 14 | 0.130 |
Why?
|
| Swine | 1 | 2016 | 67 | 0.130 |
Why?
|
| Patient Compliance | 1 | 2017 | 142 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2016 | 227 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 165 | 0.120 |
Why?
|
| Child | 1 | 2020 | 1148 | 0.120 |
Why?
|
| Time Out, Healthcare | 1 | 2016 | 1 | 0.120 |
Why?
|
| Operating Rooms | 1 | 2016 | 11 | 0.120 |
Why?
|
| Checklist | 1 | 2016 | 33 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2020 | 1386 | 0.120 |
Why?
|
| Survival Rate | 2 | 2017 | 302 | 0.120 |
Why?
|
| Tricuspid Valve | 1 | 2015 | 1 | 0.120 |
Why?
|
| Vena Cava, Inferior | 1 | 2015 | 9 | 0.120 |
Why?
|
| Balloon Occlusion | 1 | 2015 | 6 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2016 | 300 | 0.120 |
Why?
|
| Foreign Bodies | 1 | 2015 | 20 | 0.110 |
Why?
|
| Depression | 1 | 2017 | 368 | 0.110 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 173 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2013 | 29 | 0.100 |
Why?
|
| Moon | 1 | 2013 | 2 | 0.100 |
Why?
|
| Heart Bypass, Left | 1 | 2013 | 1 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 800 | 0.100 |
Why?
|
| Seasons | 1 | 2013 | 18 | 0.100 |
Why?
|
| Atrial Appendage | 1 | 2013 | 27 | 0.100 |
Why?
|
| Intraoperative Care | 1 | 2013 | 40 | 0.100 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2016 | 289 | 0.100 |
Why?
|
| Muscle, Skeletal | 2 | 2012 | 323 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2013 | 39 | 0.100 |
Why?
|
| Microcirculation | 1 | 2012 | 25 | 0.100 |
Why?
|
| Vasodilation | 1 | 2012 | 6 | 0.100 |
Why?
|
| Apoptosis | 1 | 2013 | 195 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 35 | 0.100 |
Why?
|
| Coronary Vessels | 1 | 2012 | 33 | 0.100 |
Why?
|
| Risk Adjustment | 1 | 2012 | 9 | 0.090 |
Why?
|
| Radiography | 1 | 2013 | 522 | 0.090 |
Why?
|
| Rupture, Spontaneous | 1 | 2011 | 3 | 0.090 |
Why?
|
| Intercostal Muscles | 1 | 2011 | 3 | 0.090 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 26 | 0.090 |
Why?
|
| Thromboxane A2 | 1 | 2011 | 1 | 0.090 |
Why?
|
| Vasoconstrictor Agents | 1 | 2011 | 19 | 0.090 |
Why?
|
| Muscle Contraction | 1 | 2011 | 67 | 0.090 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2011 | 5 | 0.090 |
Why?
|
| Echocardiography | 1 | 2011 | 60 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2011 | 75 | 0.080 |
Why?
|
| Animals | 1 | 2016 | 3238 | 0.080 |
Why?
|
| Fibrosis | 1 | 2007 | 30 | 0.070 |
Why?
|
| Syndrome | 1 | 2007 | 67 | 0.060 |
Why?
|
| Coronary Angiography | 1 | 2007 | 67 | 0.060 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2006 | 8 | 0.060 |
Why?
|
| Inflammation | 2 | 2021 | 223 | 0.060 |
Why?
|
| Disease Progression | 1 | 2006 | 517 | 0.050 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2013 | 2 | 0.050 |
Why?
|
| Endothelium, Vascular | 2 | 2012 | 45 | 0.050 |
Why?
|
| Chemokine CCL2 | 1 | 2021 | 19 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 37 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2021 | 68 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 58 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2021 | 29 | 0.040 |
Why?
|
| Atherosclerosis | 1 | 2021 | 44 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 109 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 21 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 144 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2020 | 146 | 0.040 |
Why?
|
| Veins | 1 | 2019 | 8 | 0.040 |
Why?
|
| Arteries | 1 | 2019 | 13 | 0.040 |
Why?
|
| Obesity | 1 | 2021 | 288 | 0.040 |
Why?
|
| Morbidity | 1 | 2017 | 49 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 62 | 0.030 |
Why?
|
| Psychometrics | 1 | 2017 | 175 | 0.030 |
Why?
|
| Systems Theory | 1 | 2016 | 2 | 0.030 |
Why?
|
| Protective Factors | 1 | 2016 | 20 | 0.030 |
Why?
|
| Medication Errors | 1 | 2016 | 12 | 0.030 |
Why?
|
| Nursing Staff, Hospital | 1 | 2016 | 26 | 0.030 |
Why?
|
| Medical Errors | 1 | 2016 | 25 | 0.030 |
Why?
|
| Patient Safety | 1 | 2016 | 32 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 388 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2016 | 127 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2016 | 110 | 0.030 |
Why?
|
| Cardioplegic Solutions | 1 | 2013 | 1 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2013 | 12 | 0.030 |
Why?
|
| Rhode Island | 1 | 2013 | 1 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 35 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 26 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2013 | 110 | 0.030 |
Why?
|
| Chicago | 1 | 2016 | 788 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 187 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 217 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 2012 | 4 | 0.020 |
Why?
|
| Nitroprusside | 1 | 2012 | 6 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2012 | 19 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 2012 | 14 | 0.020 |
Why?
|
| Substance P | 1 | 2012 | 10 | 0.020 |
Why?
|
| Tyrosine | 1 | 2012 | 22 | 0.020 |
Why?
|
| Protein Kinase C-alpha | 1 | 2012 | 8 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2012 | 8 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 33 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2012 | 35 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2012 | 28 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 282 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 350 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 131 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 55 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 369 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2012 | 47 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 380 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 56 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 174 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 477 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 229 | 0.020 |
Why?
|
| Biomarkers | 1 | 2012 | 455 | 0.020 |
Why?
|